0000356590 false 0000356590 2022-01-06 2022-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 6, 2022

 

Global Tech Industries Group, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   000-10210   83-0250943
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)

 

511 Sixth Avenue, Suite 800 New York, NY 10011

(Address of Principal Executive Offices) (Zip Code)

 

(212) -204-7926

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
Common Stock   GTII   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.01 Completion of Acquisition or Disposition of Assets

 

On January 3, 2022, Global Tech Industries Group, Inc. (the “Company”) acquired Bronx Family Eye Care, Inc. The purchase price was two million six hundred fifty thousand (2,650,000) shares of the Company’s common stock.

 

The Company is also filing this Form 8-K to provide the financial statements of Bronx Family Eye Care, Inc. and the proforma information required by Item 9.01 of Form 8-K with respect to the acquisition of Bronx Family Eye Care, Inc.

 

Item 9.01 Financial Statements and Exhibits

 

(a) Financial Statement of Businesses Acquired

 

The audited financial statements as of and for the years ended December 31, 2020, and 2019 and related notes, are filed as Exhibit 99.1 to this report and incorporated herein by reference.

 

The unaudited financial statements as of and for the nine month periods ended September 30, 2021, and 2020 and related notes, are filed as Exhibit 99.2 to this report and incorporated herein by reference.

 

(b) Proforma Financial Information

 

The unaudited pro forma condensed combined balance sheet as of September 30, 2021, and the unaudited proforma condensed combined statement of operations for the year ended December 31, 2020, and the nine months ended September 30, 2021, showing the pro forma effects of the Company’s acquisition of Bronx Family Eye Care, Inc., and related notes, are filed as Exhibit 99.3 to the report and are incorporated herein by reference.

 

(c) Exhibits

 

Exhibit No.   Description
99.1   Audited financial statements of Bronx Family Eye Care, Inc. as of and for the years ended December 31, 2020 and 2019.
99.2   Unaudited financial statements of Bronx Family Eye Care, Inc. as of and for the periods ended September 30, 2021 and 2020.
99.3   Global Tech Industries Group, Inc.’s unaudited proforma condensed consolidated financial information.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Global Tech Industries Group, Inc.
   
Date: January 7, 2022 By: /s/ David Reichman
    Chairman & CEO

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

 

 

Exhibit 99.1

 

BRONX FAMILY EYE CARE INC.

 

Index to Financial Statements

 

  Page
Independent Auditors’ Report F-1
Balance Sheets as of December 31, 2020 and 2019 F-4
Statements of Operations for the years ended December 31, 2020 and 2019 F-5
Statement of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2020 and 2019 F-6
Statements of Cash Flows for the years ended December 31, 2020 and 2019 F-7
Notes to Financial Statements F-8

 

 

 

 

 

INDEPENDENT AUDITORS’ REPORT

 

To the Stockholders
of Bronx Family Eye Care Inc.

 

Opinion

 

We have audited the accompanying financial statements of Bronx Family Eye Care Inc. (the Company), which comprise the balance sheets as of December 31, 2020 and 2019, and the related statements of operations, changes in stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes to the financial statements.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

Substantial Doubt About the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has negative working capital and negative cash flows from operations, which raises substantial doubt about its ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

 

Responsibilities of Management for the Financial Statements

 

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

 

F-2

 

 

Auditor’s Responsibilities for the Audit of the Financial Statements

 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

 

In performing an audit in accordance with generally accepted auditing standards, we:

 

Exercise professional judgment and maintain professional skepticism throughout the audit.
     
Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
     
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, no such opinion is expressed.
     
Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
     
Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

 

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

 

Pinnacle Accountancy Group of Utah

(a dba of Heaton & Company, PLLC)

Farmington, Utah

December 30, 2021

 

F-3

 

 

BRONX FAMILY EYE CARE INC.

Balance Sheets

 

    December 31,     December 31,  
    2020     2019  
ASSETS            
Current Assets                
Cash   $ 93,584     $ 18,230  
Accounts receivable     73,590       34,203  
Receivable – related party     9,036       82,575  
Total current assets     176,210       135,008  
                 
                 
Furniture and equipment, net     8,523       8,523  
Security deposit     40,000       -  
Total Assets   $ 224,733     $ 143,531  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
                 
Current Liabilities                
Accounts payable and accrued expenses   $ 54,840     $ 153,146  
Loan payable     -       13,861  
Total current liabilities     54,840       167,007  
                 
Long Term Liabilities                
EIDL Advance Loan     149,900       -  
Total Liabilities     204,740       167,007  
                 
Commitments and Contingencies     -       -  
                 
Stockholders’ Equity (Deficit)                
Common stock, $1.00 par value, 200 shares authorized, 200 shares issued and outstanding     200       200  
Additional paid-in capital     -       -  
Retained earnings (deficit)     19,793       (23,676 )
Total stockholders’ equity (deficit)     19,993       (23,476 )
                 
Total Liabilities and Stockholders’ Equity (Deficit)   $ 224,733     $ 143,531  

 

The accompanying notes are an integral part of these audited financial statements.

 

F-4

 

 

BRONX FAMILY EYE CARE INC.

Statements of Operations

 

    Years Ended December 31,  
    2020     2019  
             
Revenue   $ 1,667,793     $ 1,840,581  
Cost of sales     428,011       393,657  
Gross profit     1,239,782       1,446,924  
                 
Expenses                
General and administrative     1,170,113       1,525,921  
Total operating expenses     1,170,113       1,525,921  
                 
Income (loss) from operations     69,669       (78,997 )
                 
Other income (expense)                
Interest expense     -       (12,960 )
Total other income (expense)             (12,960 )
                 
Income before taxes     69,669       (91,957 )
Income tax provision     -       -  
                 
Net income (loss)   $ 69,669     $ (91,957 )
                 
Basic earnings per share:                
Earnings per share amount   $ 348.35     $ (459.79 )
Weighted average basic common shares outstanding     200       200  
                 
Fully diluted earnings per share:                
Earnings per share amount   $ 348.35     $ (459.79 )
Weighted average diluted common shares outstanding     200       200  

 

The accompanying notes are an integral part of these audited financial statements.

 

F-5

 

 

BRONX FAMILY EYE CARE INC.

Statements of Stockholders Equity (Deficit)

 

    Common Stock     Paid in    

Retained

Earnings

   

Total

Stockholders’

Equity

 
    Shares     Amount    

Capital

   

(Deficit)

   

(Deficit)

 
Balance December 31, 2018     200     $ 200     $             -     $ 68,281     $ 68,481  
                                         
Net loss for the year ended December 31, 2019     -       -       -       (91,957 )     (91,957 )
                                         
Balance December 31, 2019     200     $ 200     $       $ (23,676 )   $ (23,476 )
                                         
Shareholder distributions                             (26,200 )     (26,200 )
Net income for the year ended December 31, 2020     -       -       -       69,669       69,669  
                                         
Balance December 31, 2020     200     $ 200     $ -       19,793     $ 19,993  

 

The accompanying notes are an integral part of these audited financial statements.

 

F-6

 

 

BRONX FAMILY EYE CARE INC.

Statements of Cash Flows

 

    Years ended December 31,  
    2020     2019  
Cash Flows from Operating Activities                
Net income (loss)   $ 69,669     $ (91,957 )
Adjustments to reconcile net income to net cash provided by operating activities:                
Bad debt expense     75,556       -  
Changes in operating assets and liabilities:                
Accounts receivable     (114,943 )     65,554  
Receivable – related party     73,539       (81,725 )
Prepaid expenses     -       13,181  
Accounts payable and accrued expenses     (98,306 )     153,146  
                 
Net cash provided by operating activities     5,515       58,199  
                 
Cash Flows from Investing Activities                
Purchase of furniture and equipment     -       (8,523 )
Security deposit     (40,000 )     -  
Net cash used in investing activities     (40,000 )     (8,523 )
                 
Cash Flows from Financing Activities                
EIDL Loan Advance     149,900       -  
Proceeds from loan payable     -       100,000  
Repayment on loan payable     (13,861 )     (133,084 )
Shareholder Distribution     (26,200 )     -  
Net cash provided (used) in financing activities     109,839       (33,084 )
                 
Increase in cash     75,354       16,592  
                 
Cash at beginning of period     18,230       1,638  
Cash at end of period   $ 93,584     $ 18,230  
                 
Supplemental Cash Flow Information                
Cash paid for:                
Interest   $ -     $ 12,960  
Income taxes   $ -     $ -  

 

The accompanying notes are an integral part of these audited financial statements.

 

F-7

 

 

BRONX FAMILY EYE CARE INC.

Notes to Financial Statements

December 31, 2020 and 2019

 

NOTE 1 – Organization and Summary of Significant Accounting Policies

 

Bronx Family Eye Care Inc. (the “Company”) was incorporated in the State of New York on June 30, 2016. The Company is in the business of providing patients with eye consultations and exams, and selling prescription lenses and frames. The Company has elected a December 31 fiscal year end.

 

Basis of Accounting - The Company used the accrual method of accounting in accordance with accounting principles generally accepted in the United States.

 

Accounting Estimates–The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents–For the purpose of the financial statements, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

 

Inventories–Inventories, consist primarily of lenses and frames, are stated at the lower of cost or net realizable value, with cost determined using primarily the first-in-first-out (FIFO) method. The Company purchased substantially all inventories from several key suppliers. As of December 31, 2020 and 2019, the Company’s inventory balance was $0.

 

Depreciation - The cost of property and equipment is depreciated over the estimated useful lives of the related assets. The cost of leasehold improvements is depreciated over the lesser of the length of the lease of the related assets or the estimated lives of the assets. Depreciation is computed on the straight-line method which is five years for computer equipment, office equipment, and furniture and fixtures.

 

Revenue Recognition–When the Company sells a patient services or glass lens and frames, it recognizes revenue in accordance with Accounting Standards Update 2014-09 (ASC 606, Revenue from Contracts with Customers). Under ASC 606, the Company recognizes revenue upon the transfer of promised goods to customers in amounts that reflect the consideration to which the Company expects to be entitled. The Company considers revenue earned when all the following criteria are met: (i) the contract with the customer has been identified, (ii) the performance obligations have been identified, (iii) the transaction price has been determined, (iv) the transaction price has been allocated to the performance obligations, and (v) the performance obligations have been satisfied.

 

The Company recognized $1,667,793 and $1,840,581 in revenue during the years ended December 31, 2020 and 2019, respectively.

 

Accounts Receivable - In the normal course of business, the Company extends credit to its patients on a short-term basis. Although the credit risk associated with these patients is minimal, the Company routinely reviews its accounts receivable balances and makes provisions for doubtful accounts. The Company ages its receivables by date of invoice. Management reviews bad debt annually. When an account is deemed uncollectible, the Company charges off the receivable against the bad debt reserve. A considerable amount of judgment is required in assessing the realization of these receivables including the current creditworthiness of each patient and related aging of the past-due balances, including any billing disputes.

 

The allowance for doubtful accounts is based on the best information available to the Company and is re-evaluated and adjusted as additional information is received. The Company evaluates the allowance based on historical write-off experience, the size of the individual patient balances and past-due amounts. As of December 31, 2020 and 2019, the Company had an allowance for bad debt of $0 and $0, respectively. During the years ended December 31, 2020 and 2019, the Company had bad debt expense of $75,556 and $0, respectively.

 

F-8

 

 

BRONX FAMILY EYE CARE INC.

Notes to Financial Statements

December 31, 2020 and 2019

 

Fair Value of Financial Instruments - The Company applies ASC 820, “Fair Value Measurements.” This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying amounts reported in the balance sheets for cash and cash equivalents, receivables, receivables – related party, current liabilities and loans each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.

 

Income Taxes – The Company has elected to be taxed under the provisions of Subchapter S of the Internal Revenue Code. Under these provisions, the Company does not pay corporate income taxes on its taxable income. Instead, the stockholders are liable for individual income taxes on their respective income tax returns. Generally accepted accounting principles requires management to perform an evaluation of all income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax years, as defined by the various statues of limitations, for federal and state purposes.

 

The Company is required to file federal and state income tax returns. With limited exceptions, the Company is no longer subject to income tax examination for any years earlier than 2017. Management has performed its evaluation of income tax positions taken on all open income tax returns and has determined that there were no positions taken that do not meet the “more likely than not” standard. From time to time, the Company may be subject to penalties assessed by various taxing authorities, which will be classified as general and administrative expenses if they occur.

 

Recently Enacted Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that other than the pronouncement listed below none of these pronouncements will have a significant effect on its current or future earnings or operations.

 

In February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) intended to improve financial reporting for leasing transactions. The ASU will require organizations that lease assets - referred to as “lessees”- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For nonpublic companies, ASU 2020-05 deferred the effective dated for fiscal years beginning after December 15, 2021 and interim periods therein. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its financial statements.

 

 Basic and Diluted Loss Per Share - Basic loss per share is computed by dividing net loss attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing net income attributable to common shares for the period by the weighted average number of common and potential common shares outstanding during the period. Potential common shares are included in the calculation of diluted net income per share, when they are present in the financial statements, to the extent such shares are dilutive. During the years ended December 31, 2020 and 2019, the Company did not have any stock options, warrants, or other convertible or potentially-dilutive instruments issued and outstanding.

 

F-9

 

 

BRONX FAMILY EYE CARE INC.

Notes to Financial Statements

December 31, 2020 and 2019

 

The computation of earnings per share of common stock is based on the weighted average number of shares outstanding at the date of these audited financial statements.

 

    For the Years Ended December 31,  
    2020     2019  
Basic Earnings per share:                
Income (numerator)   $ (91,957 )   $ 69,669  
Shares (denominator)     200       200  
Per share amount   $ (459.79 )   $ 348.35  
Fully Diluted Earnings per share:                
Income (numerator)   $ (91,957 )   $ 69,669  
Shares (denominator)     200       200  
Per share amount   $ (459.79 )   $ 348.35  

 

NOTE 2 – Stockholders’ Equity

 

The Company has authorized 200 shares of stock with 200 shares designated common stock at a par value of $1.00 per share. There were no equity transactions during the year ended December 31, 2019 and $26,200 in shareholder distributions for the year ended December 2020.

 

NOTE 3 – Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has negative working capital as of December 31, 2020 and had negative cash flows from operations during the twelve months ended December 31, 2020. These factors, among others, indicate that there is substantial doubt that the Company will be able to continue as a going concern for a reasonable period of time.

 

The financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company intends to seek additional funding through equity or debt offerings to fund its business plan. There is no assurance that the Company will be successful in raising additional funds. COVID-19 has not had a financial impact on the Company.

 

NOTE 4 – Notes Payable

 

Loan payable

 

In June of 2018, the Company took out a Paypal loan (2018 loan) in the amount of $100,000. The 2018 loan required fifty-two weekly payments of $2,081.88.. On February 13, 2019, an additional loan (2019 loan) was extended by Paypal for $100,000. Part of the proceeds of this loan were used to pay off the 2018 loan balance. The 2019 loan required fifty-two weekly payments of $2,099.68. The 2019 loan had a balance of $13,861 as of December 31, 2019 and was paid off in full February 18, 2020.

 

F-10

 

 

BRONX FAMILY EYE CARE INC.

Notes to Financial Statements

December 31, 2020 and 2019

 

NOTE 4 – Notes Payable (continued)

 

EIDL Advance Loan

 

In September 2020, the Company received a Small Business Administration (“SBA”) Loan pursuant to the Economic Injury Disaster Loan. The Company received a loan in the amount of $150,000 from the SBA. The SBA Loan is in the form of a Note dated August 29, 2020, which matures on August 29, 2050. The SBA Loan bears interest at a rate of 3.75% per annum and is payable monthly commencing on August 29, 2021. The monthly principal and interest payment for the SBA Loan will be $731. All proceeds from this Loan will be used solely as working capital to alleviate economic injury caused by the Economic Injury Disaster.

 

At December 31, 2020, the outstanding balance was $149,900. Future maturities of notes payable are as follows:

 

Year Ending December 31,

 

2021   $ 1,319  
2022     2,986  
2023     3,376  
2024     3,505  
2025     3,639  
Thereafter     134,175  

 

NOTE 5Leases

 

In June 2016, we entered into a month-to-month lease for retail space at 432 East 149th St. in Bronx, NY. Every year in June, there is a 3% increase in the rent fees.

 

In June 2020 base rent was $4,035.79 + utility and maintenance charges. As of June 2021, base rent charge was $4,136 + maintenance and utility.

 

In June 2016, we entered into a month-to-month lease for retail space at 2336 Grand Concourse. in Bronx, NY.

In 2020 base rent was performance based and monthly totals ranged between $3,500 to $7,000. As of April 2020, we entered into an agreement for a fixed monthly of $4,500 with no rent increases during 2022. In April 2023, the lease will increase by 3%.

 

In September 1, 2018, we entered a 5-year operating lease for an retail space at 593 East Tremont in Bronx, NY with monthly payments of $3,903.84. In September of 2020, monthly rent increased to $4,020.96. In September of 2021, monthly rent increased to $4,020.96. In September of 2022, there is an option to renew for an additional 5 years.

 

In November 2020, we entered a 5-year operating lease for a retail space at 1420 St. Nichlas in Bronx, NY with monthly payments at $22,000, of which $2,000 each month is appropriated towards a security deposit. A security deposit of $40,000 was paid upon signing of the lease as of December 31, 2020, $40,000 is recorded as a security deposit asset on the balance sheet. On December 1, 2021, there will be $60,000 (3 months rent) in security deposit held by the landlord company. On this date, recurring monthly charges will be $21,500 per month. On December 1, 2022 rent charge will increase to $22,145/month. On December 1, 2023, rent charge will increase to $22,809. On December 1, 2024 rent charge will increase to $23,493. This lease is up for renewal in December 2025.

 

F-11

 

 

BRONX FAMILY EYE CARE INC.

Notes to Financial Statements

December 31, 2020 and 2019

 

NOTE 5 Leases (continued)

 

Rent expense for the years ended December 31, 2020 and 2019 was $190,033 and $186,551, respectively. These amounts were record in cost of sales in the Statement of Operations.

 

Annual Lease expenses for the following years for all 4 locations will be:

 

2021 = $ 426,504  
2022 = $ 450,874  
2023 = $ 463,684  
2024 = $ 482,566  
2025 = $ 495,724  

 

NOTE 6 Fixed Assets

 

The Company capitalizes the purchase of equipment and fixtures for major purchases more than $1,000 per item. Capitalized amounts are depreciated over the useful life of the assets using the straight-line method of depreciation which is five years for computer equipment, office equipment, and furniture and fixtures.

 

As of December 31, 2020 and 2019, the Company had furniture and equipment totaling $8,523 and $0 of accumulated depreciation. Depreciation expense for the years ending December 31, 2020 and 2019 was $0.

 

NOTE 7 – Related Party Transactions

 

As of the years ended December 31, 2020 and 2019, the Company incurred $760,518 and $764,819 respectively of administration, and professional services to EyeQ Vision Group, an entity controlled by a shareholder. These fees are referred to as Management fees and are paid in full per terms.

 

As of December 31, 2020 and 2019, related party withdrawals from accounts resulted is $9,036 and $82,575 due from EyeQ Vision Group, respectively.

 

NOTE 8 – Commitments and Contingencies

 

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company’s business. To the knowledge of management, there is no material litigation or governmental agency proceeding pending or threatened against the Company or any of its subsidiaries. Further, the Company is not aware of any material proceeding to which any director, member of senior management or owner of record or beneficially of more than five percent of any class of voting securities of the Company, or any associate of any of them is a party adverse to or has a material interest adverse to the Company.

 

NOTE 9 – Subsequent Events

 

The Company has evaluated subsequent events from the balance sheet date through the date of the financial statements were issued, and determined that there are no events requiring disclosure.

 

On March 31, 2021, the Company signed and executed a binding Stock Purchase Agreement (“SPA”) with Global Tech Industries Group, Inc (“GTII”). The SPA was signed and closed electronically on March 31, 2021. We have agreed to engage in a business combination such that the Company would become a wholly owned subsidiary of GTII subject to the terms and conditions set forth in the SPA which includes the completion of an audit.

 

F-12

 

 

Exhibit 99.2

 

BRONX FAMILY EYE CARE INC.

 

Index to Unaudited Condensed Financial Statements

 

  Page
Unaudited Condensed Balance Sheets as of September 30, 2021 and December 31, 2020 F-2
Unaudited Condensed Statements of Operations for the nine months ended September 30, 2021 and 2020 F-3
Unaudited Condensed Statement of Changes in Stockholders’ Equity (Deficit) for the nine months ended September 30, 2021 and 2020 F-4
Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 F-5
Notes to Unaudited Condensed Financial Statements F-6

 

 
 

 

BRONX FAMILY EYE CARE INC.

Unaudited Condensed Balance Sheets

 

    September 30,     December 31  
    2021     2020  
ASSETS                
Current Assets                
Cash   $ 220,909     $ 93,584  
Accounts receivable     129,710       73,590  
Receivable – related party     169,027       9,036  
                 
Total current assets     519,646       176,210  
                 
Other Assets                
Furniture and equipment, net     126,043       8,523  
Inventory     54,706       -  
Security deposit     56,000       40,000  
Total Assets     756,395       224,733  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
                 
Current Liabilities                
Accounts payable and accrued expenses   $ 126,763     $ 54,840  
                 
Total current liabilities     126,763       54,840  
                 
Long Term Liabilities                
EIDL Advance Loan     150,000       149,900  
Total Liabilities     276,763       204,740  
                 
Commitments and Contingencies     -       -  
                 
Stockholders’ Equity (Deficit)                
Common stock, $1.00 par value, 200 shares authorized, 200 shares issued and outstanding     200       200  
Additional paid-in capital     -       -  
Retained Earnings     479,432       19,793  
Total stockholders’ equity     479,632       19,993  
                 
Total Liabilities and Stockholders’ Equity (Deficit)   $ 756,395     $ 224,733  

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-2
 

 

BRONX FAMILY EYE CARE INC.

Unaudited Condensed Statements of Operations

 

    Nine Months Ended September 31,  
    2021     2020  
             
Revenue   $ 2,490,966     $ 1,245,907  
Cost of sales     535,718       218,032  
Gross profit     1,955,248       1,027,875  
                 
Expenses                
General and administrative     1,475,184       778,093  
Total operating expenses     1,475,184       778,093  
                 
Income (loss) from operations     480,064       249,781  
                 
Other income (expense)                
Interest expense     -       -  
Total other income (expense)                
                 
Income before taxes     480,064       249,781  
Income tax provision     -       -  
                 
Net income (loss)   $ 480,064     $ 249,781  
                 
Basic earnings per share:                
Earnings per share amount   $ 2,400.32     $ 1,248.91  
Weighted average basic common shares outstanding     200       200  
                 
Fully diluted earnings per share:                
Earnings per share amount   $ 2,400.32     $ 1,248.91  
Weighted average diluted common shares outstanding     200       200  

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-3
 

 

BRONX FAMILY EYE CARE INC.

Unaudited Condensed Statements of StockholdersEquity (Deficit)

Nine Months Ended September 30, 2021 and 2020

 

    Common Stock           Retained Earnings       Total Stockholders’  
    Shares     Amount     Paid in Capital     (Deficit)     Equity (Deficit)  
Balance December 31, 2019     200     $ 200     $ -      $ (23,676 )   $ (23,476 )
                                                
Net income for the period     -       -       -       249,781       249,781  
                                         
Balance September 30, 2020     200       200       -       226,105       226,305  
                                         
Balance December 31, 2020     200     $ 200     $ -     $ 19,793     $ 19,993  
                                         
Shareholder Distributions                             (20,425 )     (20,425 )
                                         
Net income for the period                             480,064       480,064  
                                         
Balance September 30, 2021     200     $ 200     $ -     $ 479,432     $ 479,632  

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-4
 

 

BRONX FAMILY EYE CARE INC.

Unaudited Condensed Statements of Cash Flows

 

    Nine Months ended September 30,  
    2021     2020  
Cash Flows from Operating Activities                
Net income (loss)   $ 480,064     $ 249,781  
Adjustments to reconcile net income to net cash provided by operating activities:                
                 
Changes in operating assets and liabilities:                
Accounts receivable     (56,120 )     (255,343 )
Receivable – related party     (159,991 )     133,757  
Inventory     (54,706 )     -  
Accounts payable and accrued expenses     71,923       (96,584 )
                 
Net cash provided by operating activities     281,170       31,611  
                 
Cash Flows from Investing Activities                
Purchase of furniture and equipment     (117,520 )     -  
Security deposit     (16,000 )     -  
Net cash used in investing activities     (133,520 )     -  
                 
Cash Flows from Financing Activities                
EIDL Loan Advance     100       149,900  
Repayment on loan payable     -       (13,861 )
Shareholder Distribution     (20,425 )     -  
Net cash provided (used) in financing activities     (20,325 )     136,039  
                 
Increase in cash     127,325       167,650  
                 
Cash at beginning of period     93,584       18,230  
Cash at end of period   $ 220,909     $ 185,880  
                 
Supplemental Cash Flow Information                
Cash paid for:                
Interest   $ -     $ -  
Income taxes   $ -     $ -  

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-5
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020

 

NOTE 1 – Organization and Summary of Significant Accounting Policies

 

Bronx Family Eye Care Inc. (the “Company”) was incorporated in the State of New York on June 30, 2016. The Company is in the business of providing patients with eye consultations and exams, and selling prescription lenses and frames. The Company has elected a December 31 fiscal year end.

 

Basis of Accounting - The Company used the accrual method of accounting in accordance with accounting principles generally accepted in the United States.

 

The accompanying unaudited condensed combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures normally included in combined financial statements have been condensed or omitted in accordance with GAAP rules and regulations. The information furnished in these interim condensed combined financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. The preparation of condensed combined financial statements in accordance with GAAP requires management to make estimates and assumptions that affect both the recorded values of assets and liabilities at the date of the condensed combined financial statements and the revenues recognized and expenses incurred during the reporting period. These estimates and assumptions affect the Company’s recognition of deferred expenses, bad debts, the carrying value of its long-lived assets and its provision for certain contingencies. The reasonableness of these estimates and assumptions is evaluated continually based on a combination of historical and other information that comes to the Company’s attention that may vary its outlook for the future. While management believes the disclosures and information presented are adequate to make the information not misleading, the Company recommends these interim condensed combined financial statements be read in conjunction with its audited financial statements and notes thereto included in its annual report for the year ended December 31, 2020. Operating results for the nine months ended September 30, 2021, are not necessarily indicative of the results to be expected for the year ending December 31, 2021.

 

Accounting Estimates – The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents – For the purpose of the financial statements, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

 

Inventories – Inventories, consist primarily of lenses and frames, are stated at the lower of cost or net realizable value, with cost determined using primarily the first-in-first-out (FIFO) method. The Company purchased substantially all inventories from several key suppliers. As of September 30, 2021 and December 31, 2020, the Company’s inventory balance was $54,706 and $0, respectively.

 

Inventory consists of two major sales product categories; Eyeglass frames and Ophthalmic lenses.

 

As of September 30, 2021, there was $10,109 of eyeglass frames, and $44,597 of Ophthalmic lenses. Lenses are assembled into the frames.

 

F-6
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020 

 

Depreciation - The cost of property and equipment is depreciated over the estimated useful lives of the related assets. The cost of leasehold improvements is depreciated over the lesser of the length of the lease of the related assets or the estimated lives of the assets. Depreciation is computed on the straight-line method which is five years for computer equipment, office equipment, and furniture and fixtures.

 

Revenue Recognition – When the Company sells a patient services or glass lens and frames, it recognizes revenue in accordance with Accounting Standards Update 2014-09 (ASC 606, Revenue from Contracts with Customers). Under ASC 606, the Company recognizes revenue upon the transfer of promised goods to customers in amounts that reflect the consideration to which the Company expects to be entitled. The Company considers revenue earned when all the following criteria are met: (i) the contract with the customer has been identified, (ii) the performance obligations have been identified, (iii) the transaction price has been determined, (iv) the transaction price has been allocated to the performance obligations, and (v) the performance obligations have been satisfied.

 

The Company recognized $2,490,965 and $1,245,907 in revenue during the nine months ended September 31, 2021 and 2020, respectively.

 

Accounts Receivable - In the normal course of business, the Company extends credit to its patients on a short-term basis. Although the credit risk associated with these patients is minimal, the Company routinely reviews its accounts receivable balances and makes provisions for doubtful accounts. The Company ages its receivables by date of invoice. Management reviews bad debt annually. When an account is deemed uncollectible, the Company charges off the receivable against the bad debt reserve. A considerable amount of judgment is required in assessing the realization of these receivables including the current creditworthiness of each patient and related aging of the past-due balances, including any billing disputes.

 

The allowance for doubtful accounts is based on the best information available to the Company and is re-evaluated and adjusted as additional information is received. The Company evaluates the allowance based on historical write-off experience, the size of the individual patient balances and past-due amounts. As of September 30, 2021 and December 31, 2020, the Company had an allowance for bad debt of $0 and $0, respectively.

 

F-7
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020

 

Fair Value of Financial Instruments - The Company applies ASC 820, “Fair Value Measurements.” This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying amounts reported in the balance sheets for cash and cash equivalents, receivables, receivables – related party, current liabilities and loans each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.

 

Income Taxes – The Company has elected to be taxed under the provisions of Subchapter S of the Internal Revenue Code. Under these provisions, the Company does not pay corporate income taxes on its taxable income. Instead, the stockholders are liable for individual income taxes on their respective income tax returns. Generally accepted accounting principles requires management to perform an evaluation of all income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax years, as defined by the various statues of limitations, for federal and state purposes.

 

The Company is required to file federal and state income tax returns. With limited exceptions, the Company is no longer subject to income tax examination for any years earlier than 2017. Management has performed its evaluation of income tax positions taken on all open income tax returns and has determined that there were no positions taken that do not meet the “more likely than not” standard. From time to time, the Company may be subject to penalties assessed by various taxing authorities, which will be classified as general and administrative expenses if they occur.

 

Recently Enacted Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that other than the pronouncement listed below none of these pronouncements will have a significant effect on its current or future earnings or operations.

 

In February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) intended to improve financial reporting for leasing transactions. The ASU will require organizations that lease assets - referred to as “lessees”- to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. For nonpublic companies, ASU 2020-05 deferred the effective dated for fiscal years beginning after December 15, 2021 and interim periods therein. The Company is currently evaluating the potential impact that the adoption of ASU No. 2016-02 may have on its financial statements.

 

Basic and Diluted Loss Per Share - Basic loss per share is computed by dividing net loss attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing net income attributable to common shares for the period by the weighted average number of common and potential common shares outstanding during the period. Potential common shares are included in the calculation of diluted net income per share, when they are present in the financial statements, to the extent such shares are dilutive. During the nine months ended September 30, 2021 and 2020, the Company did not have any stock options, warrants, or other convertible or potentially-dilutive instruments issued and outstanding.

 

F-8
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020

 

The computation of earnings per share of common stock is based on the weighted average number of shares outstanding at the date of these audited financial statements.

 

    For the Nine Months Ended September 30,  
    2021     2020  
Basic Earnings per share:            
Income (numerator)   $ 480,064     $ 249,781  
Shares (denominator)     200       200  
Per share amount   $ 2,400.32     $ 1,248.91  
Fully Diluted Earnings per share:                
Income (numerator)   $ 480,064     $ 249,781  
Shares (denominator)     200       200  
Per share amount   $ 2,400.32     $ 1,248.91  

 

NOTE 2 – Stockholders’ Equity

 

The Company has authorized 200 shares of stock with 200 shares designated common stock at a par value of $1.00 per share. There were no equity transactions during the nine months ended September 30, 2020 and $20,425 in shareholder distributions for the nine months ended September 2021. 

 

NOTE 3 – Notes Payable

 

Loan payable

 

On February 13, 2019, (2019 loan) was entered into with Paypal for $100,000. Part of the proceeds of this loan were used to pay off the outstanding balance of a prior 2018 loan. The 2019 loan required fifty-two weekly payments of $2,099.68. The 2019 loan had a balance of $13,861 as of December 31, 2019 and was paid off in full February 18, 2020. 

 

F-9
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020

 

NOTE 4 – Notes Payable (continued)

 

EIDL Advance Loan

 

In September 2020, the Company received a Small Business Administration (“SBA”) Loan pursuant to the Economic Injury Disaster Loan. The Company received a loan in the amount of $150,000 from the SBA. The SBA Loan is in the form of a Note dated August 29, 2020, which matures on August 29, 2050. The SBA Loan bears interest at a rate of 3.75% per annum and is payable monthly commencing on August 29, 2021. The monthly principal and interest payment for the SBA Loan will be $731. All proceeds from this Loan will be used solely as working capital to alleviate economic injury caused by the Economic Injury Disaster.

 

At September 30, 2021 and December 31, 2020, the outstanding balance was $150,000 and $149,900, respectively.  On March 16, 2021 the SBA Extended the deferment period for all COVID-19 EIDL until 2022

 

Future maturities of notes payable are as follows:

 

Year Ending December 31,

 

2022     2,986  
2023     3,376  
2024     3,505  
2025     3,639  
Thereafter     136,494  

 

NOTE 5 Leases

 

In June 2016, we entered into a month-to-month lease for retail space at 432 East 149th St. in Bronx, NY. Every year in June, there is a 3% increase in the rent fees.

 

In June 2020 base rent was $4,035.79 + utility and maintenance charges. As of June 2021, base rent charge was $4,136 + maintenance and utility.

 

In June 2016, we entered into a month-to-month lease for retail space at 2336 Grand Concourse. in Bronx, NY.

In 2020 base rent was performance based and monthly totals ranged between $3,500 to $7,000. As of April 2020, we entered into an agreement for a fixed monthly of $4,500 with no rent increases during 2022. In April 2023, the lease will increase by 3%.

 

In September 1, 2018, we entered a 5-year operating lease for an retail space at 593 East Tremont in Bronx, NY with monthly payments of $3,903.84. In September of 2020, monthly rent increased to $4,020.96. In September of 2021, monthly rent increased to $4,020.96. In September of 2022, there is an option to renew for an additional 5 years.

 

F-10
 

 

BRONX FAMILY EYE CARE INC.

Notes to Unaudited Condensed Financial Statements

Nine Months Ended September 30, 2021 and 2020

 

NOTE 6Fixed Assets

 

The Company capitalizes the purchase of equipment and fixtures for major purchases more than $1,000 per item. Capitalized amounts are depreciated over the useful life of the assets using the straight-line method of depreciation which is five years for computer equipment, office equipment, and furniture and fixtures.

 

As of September 30, 2021 and December 31, 2020, the Company had furniture and equipment totaling $126,043 and $8,523

 

NOTE 7 – Related Party Transactions

 

During the nine months ended September 30, 2021 and 2020, the Company incurred $1,205,562 and $760,518 respectively of administration, and professional services to EyeQ Vision Group, an entity controlled by a shareholder. These fees are referred to as Management fees and are paid in full per terms.

 

During the nine months ended September 30, 2021 and 2020, related party withdrawals from accounts resulted in receivable – related party balances of $169,027 and $9,036 due from EyeQ Vision Group as of September 30, 2021 and December 31, 2020, respectively.

 

NOTE 8 – Commitments and Contingencies

 

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company’s business. To the knowledge of management, there is no material litigation or governmental agency proceeding pending or threatened against the Company or any of its subsidiaries. Further, the Company is not aware of any material proceeding to which any director, member of senior management or owner of record or beneficially of more than five percent of any class of voting securities of the Company, or any associate of any of them is a party adverse to or has a material interest adverse to the Company.

 

NOTE 9 – Subsequent Events

 

The Company has evaluated subsequent events from the balance sheet date through the date of the financial statements were issued, and determined that there are no events requiring disclosure.

 

On December 30, 2021, Bronx Family Eye Care, Inc. has successfully concluded the requisite audit of its financial statements and is now a wholly-owned subsidiary of GTII.

 

F-11

 

 

Exhibit 99.3

 

GLOBAL TECH INDUSTRIES GROUP, INC.

Unaudited Pro Forma Condensed Consolidated Balance Sheets

 

    GTII     Bronx Family           Proforma Combined  
    September 30     September 30,     Proforma     September 30,  
    2021     2021     Adjustments     2021  
                         
ASSETS                        
CURRENT ASSETS                                
Cash and cash equivalents   $ 295,083     $ 220,909     $ -     $ 515,992  
Accounts receivable     -       129,710       -       129,710  
Receivables-related party     -       169,027       -       169,027  
Marketable securities     195,000       -       -       195,000  
                                 
Total Current Assets     490,083       519,646       -       1,009,729  
                                 
PROPERTY AND EQUIPMENT (NET)     2,143       126,043       -       128,186  
                                 
OTHER ASSETS                                
Inventory     -       54,706       -       54,706  
Security deposit     -       56,000       -       56,000  
Goodwill     -       -       6,489,868 (a)     6,489,868  
Fine art     67,845       -       -       67,845  
License     3,958       -       -       3,958  
                                 
TOTAL ASSETS   $ 564,029     $ 756,395     $ 6,489,868     $ 7,810,292  
                                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                                
                                 
CURRENT LIABILITIES                                
Accounts payable and accrued expenses   $ 1,210,007     $ 126,763       -     $ 1,336,770  
Accrued interest payable     376,007       -       -       376,007  
Notes payable in default     871,082       -       -       871,082  
Due to officers and directors     83,883       -       -       83,883  
Notes payable     200,000       -       -       200,000  
Stock deposits     490,000       -       -       490,000  
                                 
Total Current Liabilities     3,230,979       126,763               3,357,742  
                                 
LONG-TERM LIABILITIES                                
                                 
Notes payable-long term     -       150,000       -       150,000  
Total Long-Term Liabilities     -       150,000               150,000  
                                 
Total Liabilities     3,230,979       276,763       -       3,507,742  
                                 
STOCKHOLDERS’ (DEFICIT)                                
Preferred Stock, par value $.001, 50,000 authorized, 1,000 issued     1       -       -       1  
Common stock, par value $0.001 per share, 550,000,000 shares authorized; 246,722,140 and 236,572,140 issued and outstanding, respectively     246,722       200       2,450 (a)     249,372  
Additional paid-in-capital     229,725,779       -       6,486,786 (a)     236,212,565  
Retained (Deficit)     (232,639,452 )     479,432     632 (a)     (232,159,388 )
                                 
Total Stockholders’ (Deficit)     (2,666,950 )     479,632       6,489,868       4,302,550  
                                 
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)   $ 564,029     $ 756,395     $ 6,489,868     $ 7,810,292  

 

 

 

 

GLOBAL TECH INDUSTRIES GROUP, INC.

Unaudited Pro Forma Consdensed Consolidated Statements of Operations

 

    GTII     Bronx Family           Proforma  
    September 30,     September 30,     Proforma     September 30,  
    2021     2021     Adjustments     2021  
                         
                         
REVENUES, net   $ -     $ 2,490,966     $ -     $ 2,490,966  
                                 
COST OF SALES, net     -       535,718       -       535,718  
                                 
GROSS PROFIT/(LOSS)     -       1,955,248       -       1,955,248  
                                 
OPERATING EXPENSES                                
                                 
General and administrative     258,526       1,475,184               1,733,710  
Compensation and professional fees     3,860,868       -       -       3,860,868  
Charitable donations     540,113       -       -       540,113  
Depreciation     1,845       -       -       1,845  
                                 
Total Operating Expenses     4,661,352       1,475,184               6,136,536  
                                 
OPERATING INCOME (LOSS)     (4,661,352 )     480,064               (4,181,288 )
                                 
OTHER INCOME (EXPENSES)                                
                                 
Gain/(Loss) on sale of marketable securities     164,000       -       -       164,000  
Interest expense     (49,111 )     -       -       (49,111 )
                              -  
Total Other Income (Expenses)     114,889       -       -       114,889  
                                 
INCOME (LOSS) BEFORE INCOME TAXES     (4,546,463 )     480,064               (4,066,399 )
                                 
INCOME TAX EXPENSE     -       -       -       -  
                                 
NET LOSS   $ (4,546,463 )   $ 480,064             $ (4,066,399 )
                                 
OTHER COMPREHENSIVE INCOME     -       -       -       -  
                                 
COMPREHENSIVE LOSS   $ (4,546,463 )   $ 480,064             $ (4,066,399 )
                                 
BASIC AND DILUTED LOSS PER SHARE   $ (0.02 )     2,400.32             $ (0.02 )
                                 
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED     234,303,915       200       2,649,800 (b)     236,953,915  

 

 

 

 

Global Tech Industries Group, Inc.

 

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

 

1. ORGANIZATION AND BASIS OF PRESENTATION

 

On April 1, 2021, Global Tech Industries Group, Inc. (‘us”, “Public Co”, or “the Company”) acquired 100% equity interest in Bronx Family Eye Care, Inc. (“BRONX”), a New York corporation for purchase consideration of $6,969,500, payable in common stock of the company through the issuance of 2,650,000 shares (but subject to certain conditions being met by BRONX prior to closing. On December 30, 2021 the conditions were met and the share transfer agreement became effective.

 

The purchase price for BRONX was allocated to the fair value of the common stock issued by the Company. tangible assets acquired and liabilities assumed, customer lists, pharmaceutical formulas, and other intangible assets. All tangible assets acquired and liabilities assumed are recorded using the historical cost basis. The excess of the purchase price over the fair value of the net assets was allocated to goodwill.

 

The unaudited pro forma condensed consolidated financial statements (“pro forma statements”) have been compiled from and include the pro forma statements of income for the nine months ended September 30, 2021, give effect to the business combination of BRONX, as if it had occurred at the beginning of the period presented. The unaudited pro forma condensed consolidated balance sheet combining the balance sheet of Public Co as of September 30, 2021 with balance sheet of BRONX as of September 30, 2021, as if the business combination had occurred on that date. This pro forma statement does not contain all the information required for annual financial statements. Accordingly, it should be read in conjunction with the most recent annual and interim financial statements of the Company.

 

Management believes that the assumptions used provide a reasonable basis on which to present the unaudited pro forma financial data. The unaudited pro forma financial statement information has been provided for informational purposes only and should not be considered indicative of the Company’s financial position or results of operations. In addition, the unaudited pro forma financial statement information does not purport to represent the future financial position or results of operations of the Company.

 

It is management's opinion that this unaudited pro forma financial statement includes all adjustments necessary for the fair presentation of the proposed transaction in accordance with US GAAP. The pro forma statement is not intended to reflect the financial position of the Company which would have actually resulted had the proposed transaction been effected on the dates indicated.

 

2. Pro-forma Adjustments

 

The pro forma statement incorporates the following pro forma adjustments:

 

(a) The adjustment reflects the value of the share issuance of 2,650,000 shares of the Company to the shareholders of BRONX, as if the acquisition occurred on April 1, 2021. In addition, the adjustments also eliminate the original capitalization and retained earnings of BRONX, and records goodwill for the excess in common stock value over net asset value.

 

(b) The adjustments reflect the effect on basic and diluted earnings per share for combining BRONX net income for the period presented.